TrialClinical pharmacology in drug development2026

Exposure-Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial.

Mita Kuchimanchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.